📗 Cite This Artifact
Masupirdine for Alzheimer's Disease Agitation
Masupirdine AD Agitation Trial
Overview
Masupirdine (development code: SUVN-502) is a selective serotonin 6 (5-HT6) receptor antagonist developed by Suven Life Sciences Ltd. (Hyderabad, India) for the treatment of Alzheimer's disease. This compound was investigated as an adjunct therapy to background acetylcholinesterase inhibitor (donepezil) and memantine treatment for patients with moderate AD[@semba2022][@clinicaltrialsgov].
While the primary Phase 2 trial (NCT02580305) did not meet its primary cognitive endpoint, post-hoc analyses explored effects on neuropsychiatric symptoms including agitation, aggression, and psychosis — which are common and debilitating complications of Alzheimer's disease[@menon2022].
Trial Details
| Parameter | Value |
|-----------|-------|
| NCT Number | NCT02580305 (primary); NCT05397639 (agitation analysis) |
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Suven Life Sciences Ltd. |
| Intervention | Masupirdine 50 mg or 100 mg daily (oral) |
| Indication | Moderate Alzheimer's Disease (adjunct therapy) |
| Population | 564 patients (randomized 1:1:1) |
| Duration | 26 weeks |
Mechanism of Action
5-HT6 Receptor Antagonism
Masupirdine is a highly selective 5-HT6 receptor antagonist. The 5-HT6 receptor is a G-protein coupled receptor (GPCR) expressed predominantly in the central nervous system, particularly in brain regions associated with cognition and emotion:
Masupirdine AD Agitation Trial
Overview
Masupirdine (development code: SUVN-502) is a selective serotonin 6 (5-HT6) receptor antagonist developed by Suven Life Sciences Ltd. (Hyderabad, India) for the treatment of Alzheimer's disease. This compound was investigated as an adjunct therapy to background acetylcholinesterase inhibitor (donepezil) and memantine treatment for patients with moderate AD[@semba2022][@clinicaltrialsgov].
While the primary Phase 2 trial (NCT02580305) did not meet its primary cognitive endpoint, post-hoc analyses explored effects on neuropsychiatric symptoms including agitation, aggression, and psychosis — which are common and debilitating complications of Alzheimer's disease[@menon2022].
Trial Details
| Parameter | Value |
|-----------|-------|
| NCT Number | NCT02580305 (primary); NCT05397639 (agitation analysis) |
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Suven Life Sciences Ltd. |
| Intervention | Masupirdine 50 mg or 100 mg daily (oral) |
| Indication | Moderate Alzheimer's Disease (adjunct therapy) |
| Population | 564 patients (randomized 1:1:1) |
| Duration | 26 weeks |
Mechanism of Action
5-HT6 Receptor Antagonism
Masupirdine is a highly selective 5-HT6 receptor antagonist. The 5-HT6 receptor is a G-protein coupled receptor (GPCR) expressed predominantly in the central nervous system, particularly in brain regions associated with cognition and emotion:
Key Molecular Mechanisms
Why 5-HT6 in Alzheimer's Disease?
The 5-HT6 receptor offers several theoretical advantages for AD treatment:
Rationale for Agitation in AD
Agitation in Alzheimer's Disease
Agitation affects up to 70% of AD patients during the disease course and represents:
- A major cause of caregiver stress and institutionalization
- Associated with faster cognitive decline
- Limited treatment options (antipsychotics carry significant risks)
- High unmet medical need
Post-Hoc Analysis on Agitation
A published post-hoc analysis examined masupirdine's effects on agitation, aggression, and psychosis in moderate AD patients[@menon2022]:
- Population: Subset of Phase 2 trial patients
- Assessment: Neuropsychiatric Inventory (NPI) agitation domain
- Findings: Exploratory analyses suggested potential beneficial trends in agitation subdomain scores
- Limitations: Post-hoc nature requires prospective validation
The exploration of agitation outcomes led to interest in a dedicated agitation trial (NCT05397639).
Study Design
Phase 2 Trial (NCT02580305)
| Phase | Duration | Arms |
|-------|----------|------|
| Screening | 4 weeks | N/A |
| Treatment | 26 weeks | Masupirdine 50mg vs. 100mg vs. Placebo |
| Follow-up | 4 weeks | Safety monitoring |
Primary Endpoints
- Cognitive: Change from baseline in ADAS-Cog 11 (11-item Alzheimer's Disease Assessment Scale, Cognitive Subscale) at week 26
Secondary Endpoints
- Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB)
- Mini-Mental State Examination (MMSE)
- 23-item Alzheimer's Disease Co-operative Study Activities of Daily Living (ADCS-ADL)
- 12-item Neuropsychiatric Inventory (NPI)
Results
Primary Outcome
ADAS-Cog 11: The study did not meet its primary efficacy endpoint. Both masupirdine doses (50mg and 100mg) showed statistically non-significant differences compared to placebo in change from baseline at week 26[@semba2022].Secondary Outcomes
No significant treatment effects were observed in:
- CDR-SB
- MMSE
- ADCS-ADL
- NPI (overall) in the primary analysis
Safety
Masupirdine was generally safe and well tolerated:
- Adverse events similar across treatment arms
- No significant differences in serious adverse events
- Dose-proportional pharmacokinetics
Agitation Analysis (Post-Hoc)
Exploratory post-hoc analyses on NPI agitation subdomain suggested potential beneficial effects that warrant further investigation in a prospective trial focused on agitation[@menon2022].
Comparison with Other 5-HT6 Antagonists
| Drug | Company | Status | Indication |
|------|---------|--------|-------------|
| Masupirdine (SUVN-502) | Suven Life Sciences | Phase 2 complete | AD, agitation |
| Idalopirdine (Lu AE58054) | Lundbeck/Otsuka | Phase 3 failed | AD |
| SB-742457 | GlaxoSmithKline | Phase 2 | AD |
| PRX-070980 | Epix Therapeutics | Phase 1/2 | AD |
The 5-HT6 antagonist class has faced challenges in AD clinical trials, with multiple compounds failing to meet primary endpoints.
Serotonin Signaling in AD
- Serotonin System Overview
- 5-HT6 Receptor Pathway
Neuropsychiatric Symptoms in AD
- Agitation Pathophysiology
- Neuropsychiatric Symptoms
Related Drug Classes
- [Acetylcholinesterase Inhibitors](/therapeutics/acetylcholinesterase-inhibitors)
- AD Drug Repositioning
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- Clinical Trials in AD
- 5-HT6 Receptor Agonists and Antagonists
- Neuropsychiatric Symptoms in AD
- Suven Life Sciences
External Links
- [ClinicalTrials.gov - NCT02580305](https://clinicaltrials.gov/study/NCT02580305)
- [Suven Life Sciences](https://www.suven.com/)
- [5-HT6 Receptor Review - PubMed](https://pubmed.ncbi.nlm.nih.gov/36830678/)
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | clinical-trials-masupirdine-ad-agitation |
| kg_node_id | None |
| entity_type | clinical |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-6b1cf0fe8134 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-masupirdine-ad-agitation'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-clinical-trials-masupirdine-ad-agitation?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Masupirdine for Alzheimer's Disease Agitation](http://scidex.ai/artifact/wiki-clinical-trials-masupirdine-ad-agitation)
http://scidex.ai/artifact/wiki-clinical-trials-masupirdine-ad-agitation